$CTKB
Cytek Biosciences, Inc. Stock $ctkb

$ctkb Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023019777 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$49.69M	$37.09M
YoY Change	23.74%	5.77%
Cost Of Revenue	$21.53M	$16.05M
YoY Change	38.04%	7.81%
Gross Profit	$28.16M	$21.04M
YoY Change	14.66%	4.27%
Gross Profit Margin	56.67%	56.72%
Selling, General & Admin	$25.15M	$23.23M
YoY Change	47.82%	60.08%
% of Gross Profit	89.32%	110.4%
Research & Development	$12.14M	$9.974M
YoY Change	43.86%	24.29%
% of Gross Profit	43.09%	47.41%
Depreciation & Amortization	$600.0K	$1.001M
YoY Change	50.75%	26.07%
% of Gross Profit	2.13%	4.76%
Operating Expenses	$37.29M	$33.20M
YoY Change	46.51%	47.33%
Operating Profit	-$9.127M	-$12.16M
YoY Change	924.35%	415.99%
Interest Expense	$409.0K	$673.0K
YoY Change	-36.79%	14.07%
% of Operating Profit
Other Income/Expense, Net	$2.532M	$3.122M
YoY Change	-596.47%	-430.02%
Pretax Income	-$6.595M	-$9.040M
YoY Change	370.74%	173.69%
Income Tax	-$2.207M	-$2.233M
% Of Pretax Income
Net Earnings	-$4.388M	-$6.807M
YoY Change	525.07%	215.43%
Net Earnings / Revenue	-8.83%	-18.35%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.03	-$0.05
COMMON SHARES
Basic Shares Outstanding	135.7M	135.4M
Diluted Shares Outstanding	135.9M	135.5M

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$298.8M	$299.0M
YoY Change	-14.6%	-17.51%
Cash & Equivalents	$131.5M	$129.5M
Short-Term Investments	$167.3M	$169.5M
Other Short-Term Assets	$2.107M	$1.422M
YoY Change	40.94%	-15.16%
Inventory	$65.73M	$69.50M
Prepaid Expenses
Receivables	$49.62M	$43.10M
Other Receivables	$2.475M	$2.011M
Total Short-Term Assets	$424.8M	$425.6M
YoY Change	-4.16%	-3.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.59M	$15.55M
YoY Change	112.37%	139.07%
Goodwill	$19.14M	$19.14M
YoY Change	88.71%	88.71%
Intangibles	$23.68M	$24.66M
YoY Change	513.71%	469.87%
Long-Term Investments	$1.600M	$1.600M
YoY Change	0.0%
Other Assets	$3.009M	$3.006M
YoY Change	4.48%	137.82%
Total Long-Term Assets	$100.2M	$98.95M
YoY Change	102.3%	111.59%
TOTAL ASSETS
Total Short-Term Assets	$424.8M	$425.6M
Total Long-Term Assets	$100.2M	$98.95M
Total Assets	$525.1M	$524.6M
YoY Change	6.54%	7.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.082M	$5.280M
YoY Change	-54.33%	-11.57%
Accrued Expenses	$19.59M	$20.37M
YoY Change	9.81%	39.11%
Deferred Revenue	$36.67M	$31.12M
YoY Change	74.51%	59.97%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$551.0K	$582.0K
YoY Change
Total Short-Term Liabilities	$53.59M	$56.52M
YoY Change	26.54%	32.04%
LONG-TERM LIABILITIES
Long-Term Debt	$1.882M	$2.133M
YoY Change
Other Long-Term Liabilities	$2.053M	$1.867M
YoY Change	51.74%	67.29%
Total Long-Term Liabilities	$2.053M	$1.867M
YoY Change	51.74%	67.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.59M	$56.52M
Total Long-Term Liabilities	$2.053M	$1.867M
Total Liabilities	$100.9M	$101.1M
YoY Change	23.49%	28.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.23M	-$23.84M
YoY Change	27.0%	10.22%
Common Stock	$136.0K	$136.0K
YoY Change	0.74%	1.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$424.2M	$423.5M
YoY Change
Total Liabilities & Shareholders Equity	$525.1M	$524.6M
YoY Change	6.54%	7.96%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$4.388M	-$6.807M
YoY Change	525.07%	215.43%
Depreciation, Depletion And Amortization	$600.0K	$1.001M
YoY Change	50.75%	26.07%
Cash From Operating Activities	-$2.850M	$2.858M
YoY Change	-69.81%	93.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.368M	$505.0K
YoY Change	-203.01%	-35.26%
Acquisitions
YoY Change
Other Investing Activities	$4.158M	-$168.4M
YoY Change	-362.0%
Cash From Investing Activities	$2.790M	-$168.9M
YoY Change	-195.71%	21550.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	216.0K	0.000
YoY Change	-81.12%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.850M	2.858M
Cash From Investing Activities	2.790M	-168.9M
Cash From Financing Activities	216.0K	0.000
Net Change In Cash	156.0K	-167.1M
YoY Change	-101.39%	7812.22%
FREE CASH FLOW
Cash From Operating Activities	-$2.850M	$2.858M
Capital Expenditures	$1.368M	$505.0K
Free Cash Flow	-$4.218M	$2.353M
YoY Change	-48.0%	236.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001831915
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40632
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CYTEK BIOSCIENCES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2547526
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	47215 Lakeview Blvd.
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2023Q1	dei	City Area Code CityAreaCode	877
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	922-9835
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CTKB
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135666676
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129476000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296601000
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	2918000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2899000
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	169519000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	44548000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43100000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48864000
CY2023Q1	us-gaap	Inventory Net InventoryNet	69502000
CY2022Q4	us-gaap	Inventory Net InventoryNet	48154000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11107000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12954000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	425622000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	454020000
CY2023Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	23404000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20459000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15549000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13682000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13187000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13883000
CY2023Q1	us-gaap	Goodwill Goodwill	19143000
CY2022Q4	us-gaap	Goodwill Goodwill	10144000
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24664000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4331000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3006000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2957000
CY2023Q1	us-gaap	Assets Assets	524575000
CY2022Q4	us-gaap	Assets Assets	519476000
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5280000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4805000
CY2023Q1	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	1906000
CY2022Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	2163000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20366000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21126000
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10861000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7960000
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18104000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12986000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	56517000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49040000
CY2023Q1	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	16045000
CY2022Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	15596000
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13012000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13124000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11541000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12312000
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2133000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2271000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1867000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1587000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-6807000
CY2023Q1	us-gaap	Liabilities Liabilities	101115000
CY2022Q4	us-gaap	Liabilities Liabilities	93930000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135644055
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135644055
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135365381
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135365381
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	136000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	447748000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	442887000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23837000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17030000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-587000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-697000
CY2023Q1	ctkb	Noncontrolling Interest In Consolidated Subsidiary NoncontrollingInterestInConsolidatedSubsidiary	0
CY2022Q4	ctkb	Noncontrolling Interest In Consolidated Subsidiary NoncontrollingInterestInConsolidatedSubsidiary	251000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	423460000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425546000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	524575000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	519476000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37088000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35064000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16050000
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14887000
CY2023Q1	us-gaap	Gross Profit GrossProfit	21038000
CY2022Q1	us-gaap	Gross Profit GrossProfit	20177000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9974000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8025000
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11145000
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6960000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12081000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7549000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	33200000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	22534000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12162000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2357000
CY2023Q1	us-gaap	Interest Expense InterestExpense	673000
CY2022Q1	us-gaap	Interest Expense InterestExpense	590000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2143000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1652000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-374000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3122000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-946000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9040000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3303000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2233000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1145000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6807000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2158000
CY2023Q1	ctkb	Net Income Loss Allocated To Noncontrolling Interests NetIncomeLossAllocatedToNoncontrollingInterests	0
CY2022Q1	ctkb	Net Income Loss Allocated To Noncontrolling Interests NetIncomeLossAllocatedToNoncontrollingInterests	-137000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6807000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6807000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2021000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2021000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135489194
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135489194
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133902523
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133902523
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-6807000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-2158000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-42000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14000
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	152000
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6697000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2144000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425546000
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	204000
CY2023Q1	ctkb	Common Stock Withheld Related To Netshare Settlement CommonStockWithheldRelatedToNetshareSettlement	-57000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4699000
CY2023Q1	ctkb	Accumulated Marketable Securities Unrealized Gain Loss AccumulatedMarketableSecuritiesUnrealizedGainLoss	152000
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-42000
CY2023Q1	ctkb	Net Income Loss1 NetIncomeLoss1	-6807000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-235000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	423460000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	405385000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	364000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3837000
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	14000
CY2022Q1	ctkb	Net Income Loss1 NetIncomeLoss1	-2021000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-137000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	407442000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2158000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	364000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1090000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	794000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	800000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	676000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4699000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3837000
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	508000
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	74000
CY2023Q1	ctkb	Loss Gain On Investments Accretion And Amortization Net LossGainOnInvestmentsAccretionAndAmortizationNet	-1580000
CY2022Q1	ctkb	Loss Gain On Investments Accretion And Amortization Net LossGainOnInvestmentsAccretionAndAmortizationNet	0
CY2023Q1	ctkb	Interest Expenses For Accretion Of Legal Settlement Liabilities InterestExpensesForAccretionOfLegalSettlementLiabilities	544000
CY2022Q1	ctkb	Interest Expenses For Accretion Of Legal Settlement Liabilities InterestExpensesForAccretionOfLegalSettlementLiabilities	498000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6055000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1038000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3188000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5921000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	136000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4351000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	305000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2782000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1763000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	555000
CY2023Q1	ctkb	Increase Decrease In Legal Settlement Liabilities IncreaseDecreaseInLegalSettlementLiabilities	-351000
CY2022Q1	ctkb	Increase Decrease In Legal Settlement Liabilities IncreaseDecreaseInLegalSettlementLiabilities	482000
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-49000
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2581000
CY2023Q1	ctkb	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	706000
CY2022Q1	ctkb	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	291000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2858000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1480000
CY2023Q1	ctkb	Purchases Of Marketable Securities PurchasesOfMarketableSecurities	-123239000
CY2022Q1	ctkb	Purchases Of Marketable Securities PurchasesOfMarketableSecurities	0
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	505000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	780000
CY2023Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	44895000
CY2022Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0
CY2023Q1	ctkb	Payment For Additional Investment In Cytek Japan Net Of Cash Acquired PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired	235000
CY2022Q1	ctkb	Payment For Additional Investment In Cytek Japan Net Of Cash Acquired PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired	0
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-168874000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-780000
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	146000
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0
CY2023Q1	ctkb	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	57000
CY2022Q1	ctkb	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	0
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	203000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	364000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-216000
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	34313000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-167106000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2112000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299500000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	364618000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132394000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362506000
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	93000
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	75000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	139000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	228000
CY2023Q1	ctkb	Intangible Asset In Accrued Expense IntangibleAssetInAccruedExpense	4000
CY2022Q1	ctkb	Intangible Asset In Accrued Expense IntangibleAssetInAccruedExpense	40000
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Description of business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has successfully developed and manufactured its full spectrum flow cytometry platform (“instrument(s)” or “product(s)”). The Company believes its core instruments, the Aurora and Northern Lights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:"Times New Roman", serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:"Times New Roman", serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">” or “FSP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:"Times New Roman", serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">”). The Company’s FSP platform includes instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On February 28, 2023, the Company completed the acquisition of the flow cytometry and imaging (“FCI”) business unit of Luminex Corporation ("Luminex"), including relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company was incorporated in the state of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Shelf Registration Statement and At-the-Market Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">On August 26, 2022, the Company filed with the SEC an automatic shelf registration statement on Form S-3ASR (File No. 333-267118) (the “Registration Statement”). In connection with the filing of the Registration Statement, the Company also entered into a sales agreement (the “2022 Sales Agreement”) with Piper Sandler & Co. (“Piper”) as sales agent to sell from time to time up to $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million of the Company’s common stock through an “at-the-market” offering program as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Pursuant to the terms of the 2022 Sales Agreement, the aggregate compensation payable to Piper is up to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the gross proceeds from the sale of common stock sold by Piper pursuant to the 2022 Sales Agreement. Each party agreed in the 2022 Sale Agreement to provide indemnification and contribution against certain liabilities, including liabilities under the Securities Act, subject to the terms of the 2022 Sales Agreement. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company has not made any sales of common stock pursuant to the 2022 Sales Agreement.</span></p>
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited interim consolidated financial statements and accompanying notes as of the date of the unaudited interim consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span>
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27665000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17889000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129500000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296600000
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2023Q1	us-gaap	Cash Cash	118305000
CY2022Q4	us-gaap	Cash Cash	123371000
CY2023Q1	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	0
CY2022Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	29930000
CY2023Q1	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	0
CY2022Q4	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	19908000
CY2023Q1	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	0
CY2022Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	5955000
CY2023Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11171000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	117437000
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	2918000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2899000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132394000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299500000
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	24686000
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Allowance for uncollectible receivables</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company adopted ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> (“ASU 2016-13, Financial Instruments - Credit Losses “), on December 31, 2022, which was retroactively applied as of the first day of fiscal year 2022, as further described within the section below titled Recently Adopted Accounting Pronouncements. This accounting standard requires companies to measure expected credit losses on financial instruments based on the total estimated amount to be collected over the lifetime of the instrument. Prior to the adoption of this accounting standard, the Company recorded incurred loss reserves against receivable balances based on current and historical information.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Expected credit losses for uncollectible receivable balances consider both current conditions and reasonable and supportable forecasts of future conditions. Current conditions considered include pre-defined aging criteria, as well as specified events that indicate the balance due is not collectible. Reasonable and supportable forecasts used in determining the probability of future collection consider publicly available macroeconomic data and whether future credit losses are expected to differ from historical losses.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is not party to any off-balance sheet arrangements that would require an allowance for credit losses in accordance with this accounting standard.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The changes in the allowance for uncollectible receivables for the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> were as follows (in thousands):</span></p><div style="font-size:10.0pt;font-family:"Times New Roman", serif;"> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:76.406%;"/> <td style="width:1.941%;"/> <td style="width:1.0%;"/> <td style="width:19.654%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Allowance for doubtful accounts</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">102</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Utilization of allowance for doubtful accounts</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Provision for credit losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Balance at March 31, 2023</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">102</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> </table></div>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	102000
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0
CY2023Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	0
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	102000
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	34462000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27665000
CY2023Q1	ctkb	Upfront And Payment Terms UpfrontAndPaymentTerms	P30D
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	9856000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	26110000
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	900000
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	400000
CY2023Q1	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	3197000
CY2022Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1555000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14600000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	15200000
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	31116000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43100000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48864000
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	31116000
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	16505000
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	34313000
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	42181000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26925000
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4542000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4897000
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	22779000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	16332000
CY2023Q1	us-gaap	Inventory Gross InventoryGross	69502000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	48154000
CY2023Q1	ctkb	Prepaid Inventory PrepaidInventory	444000
CY2022Q4	ctkb	Prepaid Inventory PrepaidInventory	621000
CY2023Q1	us-gaap	Prepaid Rent PrepaidRent	431000
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	293000
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	769000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1466000
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	2080000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2080000
CY2023Q1	ctkb	Prepaid Value Added Tax PrepaidValueAddedTax	681000
CY2022Q4	ctkb	Prepaid Value Added Tax PrepaidValueAddedTax	0
CY2023Q1	ctkb	Prepaid Trade Show PrepaidTradeShow	543000
CY2022Q4	ctkb	Prepaid Trade Show PrepaidTradeShow	0
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2726000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2687000
CY2023Q1	ctkb	Tax Refund Receivable And Payable TaxRefundReceivableAndPayable	2011000
CY2022Q4	ctkb	Tax Refund Receivable And Payable TaxRefundReceivableAndPayable	2011000
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1422000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3796000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11107000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12954000
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	169000
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	10162000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	13911000
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1844000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1276000
CY2023Q1	ctkb	Accrued Purchases AccruedPurchases	3362000
CY2022Q4	ctkb	Accrued Purchases AccruedPurchases	2457000
CY2023Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2577000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2126000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2421000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1356000
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	20366000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21126000
CY2023Q1	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	3197000
CY2022Q4	ctkb	Customer Deposit Liability Current CustomerDepositLiabilityCurrent	1555000
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	246000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	246000
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1729000
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1421000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3003000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2931000
CY2023Q1	us-gaap	Long Term Construction Loan Current LongTermConstructionLoanCurrent	582000
CY2022Q4	us-gaap	Long Term Construction Loan Current LongTermConstructionLoanCurrent	580000
CY2023Q1	ctkb	Other Current Liabilities Other OtherCurrentLiabilitiesOther	2104000
CY2022Q4	ctkb	Other Current Liabilities Other OtherCurrentLiabilitiesOther	1227000
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10861000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7960000
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	180690000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	217778000
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	1600000
CY2023Q1	ctkb	Cashandcashequivalentsamortizedcostbasis Cashandcashequivalentsamortizedcostbasis	169350000
CY2023Q1	us-gaap	Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue	169519000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.23
CY2023Q1	ctkb	Cashandcashequivalentsamortizedcostbasis Cashandcashequivalentsamortizedcostbasis	169350000
CY2023Q1	us-gaap	Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue	169519000
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19242000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16841000
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3693000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3159000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15549000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13682000
CY2023Q1	us-gaap	Depreciation Depreciation	500000
CY2022Q1	us-gaap	Depreciation Depreciation	300000
CY2023Q1	ctkb	Aggregate Cash Consideration AggregateCashConsideration	44900000
CY2023Q1	ctkb	Schedule Of Identifiable Intangible Assets Acquired And Their Estimated Useful Lives For Amortization ScheduleOfIdentifiableIntangibleAssetsAcquiredAndTheirEstimatedUsefulLivesForAmortization	<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows:</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.325%;"/> <td style="width:1.0%;"/> <td style="width:23.616%;"/> <td style="width:1.0%;"/> <td style="width:3.242%;"/> <td style="width:29.818%;"/> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Fair Value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Useful life (years)</span></p></td> </tr> <tr style="height:9.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">(In thousands, except for years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">FCI developed technology</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,500</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Customer relationships</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,500</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Amnis tradename</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,800</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20,800</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:"Arial", sans-serif;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q1	ctkb	Discount Rate DiscountRate	0.400
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	41665000
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	45294000
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-8248000
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-5173000
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-6212000
CY2022Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3582000
CY2023Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	1500000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	26514000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5710000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1850000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1379000
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	24664000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4331000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	471000
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	453000
CY2023Q1	us-gaap	Loss Contingency Lawsuit Filing Date LossContingencyLawsuitFilingDate	February 13, 2018
CY2023Q1	ctkb	Upfront Payment UpfrontPayment	2000000.0
CY2023Q1	ctkb	Royalty Payment Duration RoyaltyPaymentDuration	P10Y
CY2023Q1	ctkb	Mile Stone Payment MileStonePayment	6000000.0
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18M
CY2023Q1	ctkb	Cost Of Sales Related To Royalty Expense CostOfSalesRelatedToRoyaltyExpense	0
CY2022Q1	ctkb	Cost Of Sales Related To Royalty Expense CostOfSalesRelatedToRoyaltyExpense	800000
CY2023Q1	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	500000
CY2022Q1	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	500000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	17.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8400455
CY2023Q1	ctkb	Legal Settlement Liability Current LegalSettlementLiabilityCurrent	1906000
CY2022Q4	ctkb	Legal Settlement Liability Current LegalSettlementLiabilityCurrent	2163000
CY2023Q1	ctkb	Legal Settlement Liability Non Current LegalSettlementLiabilityNonCurrent	16045000
CY2022Q4	ctkb	Legal Settlement Liability Non Current LegalSettlementLiabilityNonCurrent	15596000
CY2023Q1	ctkb	Legal Settlement Liability LegalSettlementLiability	17951000
CY2022Q4	ctkb	Legal Settlement Liability LegalSettlementLiability	17759000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7578635
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.76
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	37200000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1083739
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.49
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	202217
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	48037
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.85
CY2023Q1	ctkb	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod	11665
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30887000
CY2023Q1	ctkb	Right Of Use Assets Obtained In Exchange For New Lease Obligations RightOfUseAssetsObtainedInExchangeForNewLeaseObligations	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4397107
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.41
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M3D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25270000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.92
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.04
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4699000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3837000
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	338000
CY2022Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	249000
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.247
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.347
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	898000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	782000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	24000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000
CY2023Q1	us-gaap	Lease Cost LeaseCost	922000
CY2022Q1	us-gaap	Lease Cost LeaseCost	795000
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	66000
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	66000
CY2023Q1	ctkb	Operating Cash Outflows Payments On Operating Leases OperatingCashOutflowsPaymentsOnOperatingLeases	776000
CY2022Q1	ctkb	Operating Cash Outflows Payments On Operating Leases OperatingCashOutflowsPaymentsOnOperatingLeases	348000
CY2022Q1	ctkb	Right Of Use Assets Obtained In Exchange For New Lease Obligations RightOfUseAssetsObtainedInExchangeForNewLeaseObligations	14564000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13187000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13883000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3003000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2931000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11541000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12312000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14544000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	15243000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y5M19D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2491000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3098000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2681000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2579000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2315000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2395000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15559000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1015000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14544000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2126000
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1760000
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1189000
CY2022	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	2841000
CY2023Q1	us-gaap	Product Warranty Expense ProductWarrantyExpense	738000
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	2475000
CY2023Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2577000
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2126000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6807000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2158000
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	137000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6807000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6807000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2021000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2021000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135489194
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133902523
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135489194
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133902523
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3200000
CY2023Q1	us-gaap	Revenues Revenues	37088000
CY2022Q1	us-gaap	Revenues Revenues	35064000
CY2023Q1	us-gaap	Noncurrent Assets NoncurrentAssets	15549000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	13682000

Files In Submission

Name	View Source	Status
0000950170-23-019777-index-headers.html	Edgar Link	pending
0000950170-23-019777-index.html	Edgar Link	pending
0000950170-23-019777.txt	Edgar Link	pending
0000950170-23-019777-xbrl.zip	Edgar Link	pending
ctkb-20230331.htm	Edgar Link	pending
ctkb-20230331.xsd	Edgar Link	pending
ctkb-ex10_1.htm	Edgar Link	pending
ctkb-ex31_1.htm	Edgar Link	pending
ctkb-ex31_2.htm	Edgar Link	pending
ctkb-ex32_1.htm	Edgar Link	pending
ctkb-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img176792220_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
ctkb-20230331_cal.xml	Edgar Link	unprocessable
ctkb-20230331_def.xml	Edgar Link	unprocessable
ctkb-20230331_lab.xml	Edgar Link	unprocessable
ctkb-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctkb-20230331_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTKB
Cytek Biosciences, Inc. Stock $ctkb

2023 Q2 Form 10-Q Financial Statement

#000095017023019777 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTKB Cytek Biosciences, Inc. Stock $ctkb

2023 Q2 Form 10-Q Financial Statement

#000095017023019777 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTKB
Cytek Biosciences, Inc. Stock $ctkb